In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Intense antithrombotic therapy is necessary for long-term treatment in patients with symptomatic peripheral artery disease after acute myocardial infarction and primary PCI

Session Acute Coronary Syndromes ePosters

Speaker Zuzana Motovska

Event : ESC Congress 2020

  • Topic : coronary artery disease, acute coronary syndromes, acute cardiac care
  • Sub-topic : Pharmacotherapy
  • Session type : ePosters

Authors : Z Motovska (Prague,CZ), 0 Hlinomaz (Brno,CZ), P Kala (Brno,CZ), J Knot (Prague,CZ), J Jarkovsky (Brno,CZ), M Hromadka (Plzen,CZ), I Varvarovsky (Pardubice,CZ), J Dusek (Hradec Kralove,CZ), F Tousek (Ceske Budejovice,CZ), S Simek (Prague,CZ), A Vodzinska (Trinec,CZ), M Svoboda (Brno,CZ), P Widimsky (Prague,CZ)

Z Motovska1 , 0 Hlinomaz2 , P Kala3 , J Knot1 , J Jarkovsky4 , M Hromadka5 , I Varvarovsky6 , J Dusek7 , F Tousek8 , S Simek9 , A Vodzinska10 , M Svoboda4 , P Widimsky1 , 1Charles University Prague, 3rd Faculty of Medicine, Faculty Hospital Kralovske Vinohrady - Prague - Czechia , 2International Clinical Research Center - Brno - Czechia , 3Univ. Hospital Bohunice - Brno - Czechia , 4Institute of Biostatistics and Analyses of Masaryk University - Brno - Czechia , 5Charles University and Univ. Hospital, Department of Cardiology - Plzen - Czechia , 6Cardiology Center AGEL a.s. - Pardubice - Czechia , 7University Hospital Hradec Kralove - Hradec Kralove - Czechia , 8Regional Hospital of Ceske Budejovice - Ceske Budejovice - Czechia , 9First Faculty of Medicine and General Teaching Hospital - Prague - Czechia , 10Hospital Podlesi - Trinec - Czechia ,

On behalf: PRAGUE-18 study investigators

Acute Coronary Syndromes: Pharmacotherapy

Background. Evidence about the benefit of intense dual antiplatelet therapy in patients with peripheral artery disease (PAD) and concomitant coronary artery disease is controversial.

Purpose. To analyze the impact of symptomatic PAD comorbidity on prognosis of patients with acute myocardial infarction (AMI) treated with primary PCI and intense antithrombotic medication.

Methods. The study is a post hoc analysis of the multicenter randomized PRAGUE-18 study (prasugrel vs. ticagrelor in primary PCI). During the 12-month follow-up switch to clopidogrel for economic reasons was allowed if approved by treating physician. Out of the whole study population (N=1230), symptomatic PAD was present in 2.9%.

Results. No significant difference related to the presence of PAD was observed neither in primary net clinical endpoint (death, reinfarction, urgent target vessel revascularization, stroke, severe bleeding requiring transfusion or prolonged hospitalization) at 7th day nor in combined ischemic endpoint (CV death, MI, stroke) within 30-days. At one year, the risk of death was higher in patients with concomitant PAD (Figure).  But, the risk of death was significantly increased only in patients who switched to clopidogrel [6.37 (2.16 – 18.84), p = 0.001]. The difference in risk of death related to the presence of symptomatic PAD didn’t reach significance [3.02 (0.72 – 12.61), p = 0.13] in patients who continued on ticagrelor/prasugrel. The landmark analysis from the day 30 up until the end of the study showed that the risks of CV death and all-cause death were significantly higher in PAD patients [6.13 (1.37 – 27,38), p = 0.018 and 9.66 (3.61 – 25.87), p < 0,001 respectively]. The significant impact of PAD on the long-term outcome, however, was also present only in patients, who switched to clopidogrel. No difference was found in the occurrence of bleeding events between patients with (8.3%) and without (11.1%) PAD throughout the whole study period (p=0.66). 

Conclusion. Presence of PAD significantly impacts prognosis of patients after AMI; especially in those who de-escalate the antiplatelet medication. Long-term intense antithrombotic medication is necessary for patients after AMI with concomitant symptomatic PAD.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Get your access to resources

Join now
  • 1ESC Professional Members – access all ESC Congress resources 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now
logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are